VRTX Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free http://www.biomedreports.com/2012022389941/vertex-announces-12-week-on-treatment-data-and-svr4-from-phase-2-study-of-interferon-free-all-oral-treatment-regimen-of-incivek®-vx-222-and-ribavirin-in-people-with-genotype-1-hepatitis.html stockcharts.com/c-sc/sc?s=vrtx&p=d&yr=0&mn=3&dy=0&id=p80920423002